413 related articles for article (PubMed ID: 30099369)
1. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
2. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
3. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Simmons AD; Nguyen M; Pintus E
BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
[TBL] [Abstract][Full Text] [Related]
5. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
6. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
7. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Castro E; Mateo J; Olmos D; de Bono JS
Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
[TBL] [Abstract][Full Text] [Related]
10. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
11. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
13.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
14. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
16. Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
McFarland TR; Tandar CE; Agarwal N; Swami U
Cancer Treat Res Commun; 2021; 29():100480. PubMed ID: 34700141
[TBL] [Abstract][Full Text] [Related]
17. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
18. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract][Full Text] [Related]
20. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]